


# Managing the Study (Part 2)

John Collins  
Ed Hughes

# Mahone Bay



# Mader's Cove



MAHONE BAY

Population: 981



# Day 1. Planning your research

## **Before you begin.**

What is the question?

Researching the background.

The design architecture.

## **What to study: patients, records or publications**

Internal vs external validity

Primary, secondary outcomes

Sample size assumptions.

## **Managing the study**

CC and cohorts: consecutive accrual

Randomization: allocation sequence

Follow-up, contamination, co-intervention

Systematic review: acquisition & selection

## **Finishing the study**    Analysis plan

Relevance, funding, logistics

# What is being published?

Articles 2000-2010	Number	% of Total
All AHR citations*	19,563	0.3
		% of AHR
Human	14,170	72
Epidemiological studies	3,340	17
Reviews	2,450	13
RCTs	923	5
Meta-analyses	194	1
All citations 2000-2010	6,587,780	

\* Reproductive Techniques, Assisted

## How many meta-analyses are published?

Articles 2000-2010	Number	% of Total
All citations*	557	
Human	506	91
Reviews (vs editorials, letters)	465	83
Meta-analyses	31	6

\*Human Reproduction Update

# Getting help on methods

Cochrane  
Handbook

Comprehensive detailed methodology for reviews [ww.cochrane-handbook.org](http://www.cochrane-handbook.org)

PRISMA

Preferred Reporting Items for Systematic Reviews and Meta-Analyses (replaces QUOROM)  
[ww.prisma-statement.org](http://www.prisma-statement.org)

MOOSE

Meta-analysis Of Observational Studies in Epidemiology. *JAMA* 2000; 283:2008-12

Schlesselman, J.

A practitioner's guide to meta-analysis. *Hum Reprod* 1997;12:1851-63

# Systematic review: definitions

## **Official version**

**Systematic reviews** use pre-planned methods and an assembly of original studies that meet their criteria as 'subjects'. They synthesize the results of these primary investigations using strategies that limit bias and random error.

<http://www.cochranemsk.org/cochrane/review/default.asp?s=1>

# Systematic review: definitions

## Populist version

A **systematic review** is a literature review focused on a single question that tries to identify, appraise, select and synthesize all high quality research evidence relevant to that question.

[http://en.wikipedia.org/wiki/Systematic\\_review](http://en.wikipedia.org/wiki/Systematic_review)

A **Meta-analysis** is simply one of several analysis strategies that can be used to synthesize the results of a systematic review.

# Steps in systematic review

1. Formulate the problem
2. Locate and select studies
3. Critically appraise the studies
4. Collect the relevant data
5. Analyze and present the results
6. Interpret the results
7. Improve and update reviews

*Higgins & Green, 2009. Cochrane Handbook*

# Managing the study (part 2)

1. Systematic review: **acquisition** & selection

## **Finishing the study**

2. Analysis plan

3. Logistics, relevance and funding

# Systematic review acquisition procedures

What literature addresses your question?

- Laboratory studies
- Epidemiological studies
- Qualitative studies
- Randomized controlled trials

# Databases to search: clinical

Cochrane Central Register of Controlled Trials (CENTRAL)

MEDLINE

EMBASE

CINAHL: *Cumulative Index to Nursing and Allied Health  
Literature*

# Acquisition procedures

The databases generally considered to be the most important sources to search are **CENTRAL, MEDLINE and EMBASE.**

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from [www.cochrane-handbook.org](http://www.cochrane-handbook.org).

# Other search strategies

- National and regional databases
- Subject-specific databases
- Citation indexes
- Dissertations and theses databases
- Grey literature databases
- Journals and other non-bibliographic-database sources
- Handsearching
- Conference abstracts or proceedings
- Other reviews, guidelines and reference lists Web searching



# Unpublished studies (1)

A debatable subject.



- Efforts should be made to identify unpublished studies.
- Ongoing trials should be identified and tracked for possible inclusion in reviews on completion.

From Higgins and Green, 2009: the Cochrane Handbook


## Unpublished and ongoing studies (2)

### Another viewpoint.

- Studies that are published in the medical literature are available for public scrutiny. They form the basis of informed debate, and decision making by physicians, patients, regulatory agencies, and others.
- The fact that publication bias can occur serves to emphasize that much of scientific knowledge is provisional.

Schlesselman 1997. Hum Reprod 12:1851-1863. doi:  
10.1093/humrep/12.9.1851

**Funnel plots for meta-analyses refuted and confirmed by subsequent mega trials: intravenous magnesium (left) and streptokinase (right) in acute myocardial infarction.**



*Points indicate odds ratios from small and medium sized trials, diamonds indicate combined odds ratios with 95% confidence intervals from meta-analysis of these trials, and squares indicate odds ratios with 95% confidence intervals from mega trials.*

*(The list of trials is available from the authors)*

# Qualitative literature databases

CINAHL: *Cumulative Index to Nursing and Allied Health Literature*

PsycINFO

Social Sciences Citation Index

Sociological Abstracts

SAGE: Nursing and Health Sciences, Psychology, and Sociology

Broad search strategy: the exploded MeSH term  
“Reproductive Techniques, Assisted” includes

Embryo Transfer

Fertilization in Vitro

Sperm Injection, Intracytoplasmic

Oocyte Retrieval

Gamete Intrafallopian Transfer

Zygote Intrafallopian Transfer

Sperm Retrieval

Oocyte Donation

Ovulation Induction

Superovulation

Insemination, Artificial

Heterologous, Homologous

Posthumous Conception

The MeSH term pre-implantation diagnosis has to be added.

# Summary points

1. Search CENTRAL, MEDLINE and EMBASE.
2. Some topics require searching national, regional and subject-specific databases.
3. Consider conference abstracts and other grey literature.
4. Consult reference lists: other reviews, guidelines, included and excluded studies.
5. Efforts should be made to identify unpublished studies.
6. Identify ongoing trials for possible inclusion on completion.
7. Check trials registers and trials results registers.

# Managing the study (part 2)

1. Systematic review: acquisition & **selection**

## **Finishing the study**

2. Analysis plan

3. Logistics, relevance and funding

# Study selection

- Set up eligibility criteria before search begins.
- Do a dry run.
- Modify the eligibility criteria if necessary.


# Process for selecting studies

- **Merge search results** using reference management software, and remove duplicate records of the same report.
- **Examine titles and abstracts** to remove obviously irrelevant reports (authors should generally be over-inclusive at this stage).
- **Retrieve full text** of the potentially relevant reports.
- **Link** together multiple reports of the same study.

# Process for selecting studies

- **Examine full-text reports** for compliance of studies with eligibility criteria.
- **Correspond with investigators**, where appropriate, to clarify study eligibility (it may be appropriate to request further information, such as missing results, at the same time).
- **Make final decisions** on study inclusion and proceed to data collection.

# PRISMA 2009 Flow Diagram



Moher et al (2009). *The PRISMA Statement*. *PLoS Med* 6(6): e1000097.

# Managing the study (part 2)

1. Systematic review: acquisition & selection

## **Finishing the study**

**2. Analysis plan**

**Depends on type of study**

3. Logistics, relevance and funding

# Analysis plan by study type

Primary Study		Outcome	Typical Analysis
	Laboratory	Continuous	Z score, t test, regression
	Clinical	Event	chi square, logistic regression
Systematic review			
	Laboratory	Continuous	weighted mean difference
	Clinical	Event	weighted average RRs, RDs

Focus on clinical studies

# Presenting risk and NNT

*In Vitro Fertilization with Preimplantation Genetic Screening. Mastenbroek et al, NEJM July 2007; 357 (1) 9-17*

- PGS resulted in lower live birth rate\*  
24% [49 of 206] vs. 35% [71 of 202]
  - absolute risk diff 11%
  - NNH 10 (1/absolute difference)
  - Rate ratio (Relative Risk) 0.68
  - 95% CI, 0.5 to 0.92
  - p=0.01

# Presenting Measure of Probability: Risk vs Odds

- Risk of drawing a spade from 52 cards  
=  $13/52 = 1/4 = 25\%$
- Odds of a spade from 52 cards, 1:3  
=  $13/39 = 1/3 = 33\%$

# Relative Risk and Odds Ratios

	Birth	No birth	Total
PGS	a 49	b 157	206
No PGS	c 71	d 131	202
	120	288	408

$$RR = a/a+b / c/c+d$$

$$= 49/206 / 71/202$$

$$RR = 0.68$$

$$OR = a \times d / c \times b$$

$$= 49 \times 131 / 71 \times 157$$

$$OR = 0.58$$

# Relative Risk and Odds Ratios

	Birth	No birth	Total
PGS	a 88	b 118	206
No PGS	c 128	d 74	202
	216	192	408

$$RR = a/a+b / c/c+d$$

$$= 88/206 / 128/202$$

$$RR = 0.68$$

$$OR = a \times d / c \times b$$

$$= 88 \times 74 / 128 \times 118$$

$$OR = 0.43$$

# Presenting Measure of Probability: Risk vs Odds

- Present absolute difference (RD), relative risk (RR) and number needed to treat, to patients considering care
- Avoid odds ratios (OR) where possible

Most clinical studies use a two-by-two table

	<b>Success</b>	<b>Failure</b>	<b>Total</b>
Group 1	$n_{11}$	$n_{12}$	$n_{1+}$
Group 2	$n_{21}$	$n_{22}$	$n_{2+}$
Total	$n_{+1}$	$n_{+2}$	$N$

Diagnostic studies (disease and no disease)

Case control studies (disease and no disease)

Cohort studies

Randomized controlled trials

# Analysis plan for clinical studies

1. Analyze comparability of groups
2. Chi square if no imbalance
3. Logistic regression if important imbalance
4. Report rate differences and relative risks  
(may need to convert ORs to RRs)
5. Estimate NNT where appropriate



# Systematic review: assessment for bias

- **Sequence generation.**
- **Allocation concealment.**
- **Blinding of participants, personnel and outcome assessors** *Assessments should be made for each main outcome (or class of outcomes).*
- **Incomplete outcome data** *Assessments should be made for each main outcome (or class of outcomes).*
- **Selective outcome reporting.**
- **Other sources of bias.**

# Another view of study quality

Arguments over the quality of studies, how it should be determined and what should be made of it, are in fact tangential disputes over what really is at issue, namely, which studies have the right results?

# Systematic review meta-analysis

- Meta-analysis is a weighted average of individual study effects
- For example, if you bought three bags of groceries
  - 2 pounds of salt @ \$3.00 a pound,
  - 3 pounds of sugar @ 1.00 a pound, and
  - 4 pounds of flour @ 0.45 cents a poundthe average cost of your staple goods would be  
$$(2*3+3*1+4*0.45)/(2+3+4) = \$1.20 \text{ per pound}$$
- Similarly, a meta-analysis is the sum of each study's weight times its effect, divided by the sum of the all weights.

# Meta-analysis methods

$$\text{generic inverse-variance weighted average} = \frac{\sum Y_i (1/SE_i^2)}{\sum (1/SE_i^2)}$$

- $Y = \text{OR, RR or RD}$
- $1/SE^2 = \text{weight} = \text{inverse of the variance.}$

# Meta-analysis issues

- Heterogeneity: some factor other than the treatment is contributing to variability among the published outcomes.
- A “random effects model” considers that the individual study estimates come from a universe of possible effects, rather than from a discrete collection of studies - conservative approach
- “Fixed effects model” doesn’t address potential heterogeneity and generates more liberal (narrow) confidence intervals
- Views differ – heterogeneity invalidates a summary effect ; heterogeneity is normal: search for factors

# Looking for Heterogeneity

- Clinical :
  - population
  - intervention
  - outcome
- Study quality
- Statistical :
  - $I^2$
  - Breslow-Day, Chi square

# Extended meta-analysis

Sensitivity or sub group analysis: challenges alpha assumptions

Categorical meta-analysis

- allows exploration of factors causing heterogeneity

- allows for an adjusted mean difference between sub-groups

Meta-regression

- corresponds to linear regression

- allows for a regression co-efficient to estimate the effect of study quality, mean age, etc. on the summary relative risk.

# Meta-analysis programs

Review Manager (Revman 5)	Cochrane Collaboration	<a href="http://ms.cochrane.org/revman">ms.cochrane.org/revman</a>
Comprehensive meta-analysis (CMA)	Biostat: NIH support	<a href="http://www.meta-analysis.com/">www.meta-analysis.com/</a>
Meta-Win	No longer available	<a href="http://www.sinauer.com">www.sinauer.com</a>

# Managing the study (part 2)

1. Systematic review: acquisition & selection

## **Finishing the study**

2. Analysis plan

Depends on type of study

**3. Logistics, relevance and funding**

# Logistics

Summarize from your procedures section:

- How many centres will be involved
  - What are recruitment targets
  - Multi-center management has significant issues
- Who will recruit patients?
  - Dedicated research “assistant”?
  - Process to ensure recruitment and consent done?
- How long will the study last?
  - Process to monitor recruitment targets met

# Relevance

Make a statement about relevance to:

- Patients
  - How will it help them?
- body of research
  - Has question been answered at all or in less valid way?
- clinical progress
  - Same as relevance to patients?
- funding agency
  - Be sure agency includes question in their remit

# Funding

- Breakdown costs by personnel, supplies, capital costs
  - Get help with this. Important to avoid mistakes
- Consider relevant funding agencies
  - Send out for pre-review and ask others for alternative sources
- Make sure relevance section applies to the agency in question

# Managing the study (part 2)

1. Systematic review: acquisition & selection

## **Finishing the study**

2. Analysis plan
  - Depends on type of study
3. Logistics, relevance and funding

## **Summary point: start with a one-page outline.**

- |                          |                                   |
|--------------------------|-----------------------------------|
| <b>1. Background</b>     | <b>5. Intervention</b>            |
| <b>2. Question</b>       | <b>6. Outcomes of interest</b>    |
| <b>3. Planned design</b> | <b>7. Analysis plan</b>           |
| <b>4. Assembly</b>       | <b>8. Expected methods issues</b> |











